You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

CLINICAL TRIALS PROFILE FOR LIDOCAINE; TETRACAINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lidocaine; Tetracaine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00107822 ↗ Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Children Completed ZARS Pharma Inc. Phase 3 2005-04-01 The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in children. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00107835 ↗ Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults Completed ZARS Pharma Inc. Phase 3 2005-05-01 The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
NCT00110253 ↗ Duration of Skin Numbing Effect Created by the S-Caine™ Peel Completed ZARS Pharma Inc. Phase 3 2005-06-01 S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a new skin numbing cream made of lidocaine and tetracaine. The purpose of this study is to evaluate and measure the length of time the S-Caine Peel numbs the skin, when applied for 30 and 60 minutes.
NCT00110734 ↗ S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults Completed ZARS Pharma Inc. Phase 3 1969-12-31 There is pain associated with laser-assisted tattoo removal. For this reason, some form of anesthesia is commonly used to eliminate or minimize the pain. This anesthesia is usually a topical local anesthetic cream or ointment spread over the skin. The purpose of this study is to further estimate the effectiveness of S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) for treating pain during laser-assisted tattoo removal.
NCT00110747 ↗ S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults Completed ZARS Pharma Inc. Phase 3 2005-06-01 Lasers are used for non-ablative resurfacing of facial rhytides, atrophic scars, and a variety of epidermal and dermal lesions. Pain associated with the non-ablative laser treatment has been described as moderate to severe. For this reason, local anesthesia is commonly used to eliminate or minimize the pain. S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) is a eutectic formulation of lidocaine and tetracaine. The purpose of this study is to evaluate if S-Caine Peel is effective in providing topical local dermal anesthesia for non-ablative facial laser resurfacing in adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lidocaine; Tetracaine

Condition Name

Condition Name for Lidocaine; Tetracaine
Intervention Trials
Pain 17
Healthy 3
Laceration of Skin 2
Lacerations 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lidocaine; Tetracaine
Intervention Trials
Lacerations 6
Macular Degeneration 3
Pain, Postoperative 2
Retinal Vein Occlusion 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lidocaine; Tetracaine

Trials by Country

Trials by Country for Lidocaine; Tetracaine
Location Trials
United States 52
Canada 5
China 3
Italy 3
Saudi Arabia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lidocaine; Tetracaine
Location Trials
Texas 7
New York 6
Florida 5
California 4
Michigan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lidocaine; Tetracaine

Clinical Trial Phase

Clinical Trial Phase for Lidocaine; Tetracaine
Clinical Trial Phase Trials
Phase 4 13
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lidocaine; Tetracaine
Clinical Trial Phase Trials
Completed 40
Unknown status 7
Recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lidocaine; Tetracaine

Sponsor Name

Sponsor Name for Lidocaine; Tetracaine
Sponsor Trials
ZARS Pharma Inc. 16
Lawson Health Research Institute 3
Cairo University 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lidocaine; Tetracaine
Sponsor Trials
Other 48
Industry 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Lidocaine and Tetracaine: Clinical Trials, Market Analysis, and Projections

Introduction to Lidocaine and Tetracaine

Lidocaine and tetracaine are widely used local anesthetics that have been integral in various medical procedures for pain management and anesthesia. Here, we will delve into recent clinical trials, market analysis, and future projections for these drugs.

Clinical Trials and Efficacy

Pain Management in Pediatric Patients

A recent study focused on the use of lidocaine plus tetracaine patches in pediatric patients undergoing lumbar punctures for intrathecal chemotherapy. The study aimed to evaluate the efficacy of these patches in reducing pain and the dose of propofol required during the procedure. While the lidocaine plus tetracaine patch did not significantly reduce the total dose of propofol, it did improve pain management compared to placebo patches. However, the recovery time was longer in the patch group, indicating a need for careful consideration of the trade-offs between pain relief and recovery times[1].

Cosmetic and Dermatological Procedures

In the realm of cosmetic procedures, a Phase 3 study evaluated the efficacy and safety of a lidocaine/tetracaine 7%/7% cream for soft tissue augmentation with hyaluronic acid. The results showed that this cream provided significant pain relief and was safe and well-tolerated, with no related adverse events reported. This study underscores the effectiveness of lidocaine and tetracaine in minimizing pain during superficial dermatological procedures[4].

Market Analysis

Global Lidocaine Market

The global lidocaine market is experiencing substantial growth, driven by its extensive use in various medical applications. In 2023, the market was valued at USD 2.43 billion and is projected to reach USD 3.68 billion by 2031, growing at a CAGR of 5.30% during the forecast period. Key drivers include the increasing prevalence of chronic pain conditions, the rise in surgical and dental procedures, and advancements in formulation technologies such as liposomal lidocaine, which offers sustained release and prolonged pain relief[2].

Market Segmentation

The lidocaine market is segmented by formulation (injections, creams, ointments, gels, aerosol liquids), application (dentistry, cardiac arrhythmia, epilepsy, cosmetics), and distribution channels (hospital pharmacies, retailer pharmacies). The expansion of lidocaine applications beyond traditional uses, such as in dermatology for conditions like eczema and psoriasis, further broadens its market potential[2].

Regional Growth

The Asia-Pacific region is expected to be the fastest-growing market for lidocaine formulations, driven by the increasing number of dental procedures, cosmetic treatments, and plastic surgeries. The growing middle class and higher disposable incomes in countries like China and India are fueling this demand[2].

Market Projections

Future Growth Drivers

The lidocaine market is poised for sustained growth due to several factors:

  • Advanced Delivery Systems: Innovations such as liposomal lidocaine are enhancing the efficacy and safety of lidocaine formulations, providing prolonged analgesia with fewer systemic side effects[2].
  • Increasing Surgical and Dental Procedures: The rise in outpatient procedures and the growing acceptance of lidocaine for cosmetic applications are driving market demand[2].
  • Regulatory Approvals: New lidocaine formulations are receiving regulatory approvals, facilitating market expansion and encouraging companies to invest in research and development[2].

Challenges and Restraints

Despite the growth potential, the lidocaine market faces challenges such as adverse reactions and side effects. However, advancements in formulation technologies are mitigating these risks by providing safer and more effective pain relief options[2].

Key Applications and Trends

Pain Management Strategies

Lidocaine is increasingly being used as part of multimodal pain management strategies to reduce opioid use and avoid possible side effects. For instance, lidocaine transdermal patches have been used to reduce pain intensity in neuropathic cancer patients already treated with opioids[5].

Cosmetic Procedures

The use of lidocaine/tetracaine 7%/7% cream in cosmetic procedures such as soft tissue augmentation, laser resurfacing, and tattoo removal is gaining traction due to its efficacy in providing local dermal anesthesia[4].

Expert Insights and Statistics

  • Market Share: Lidocaine dominated the local anesthesia drugs market with a 28.7% share in 2023, highlighting its extensive use in injectable and topical anesthetics[5].
  • Growth Rate: The global lidocaine market is expected to grow at a CAGR of 5.30% from 2024 to 2031[2].
  • Regional Growth: The Asia-Pacific region is projected to be the fastest-growing market, driven by increasing demand for cosmetic and surgical procedures[2].
"The lidocaine market is witnessing a significant trend toward the development of advanced delivery systems, enhancing the efficacy and safety of lidocaine formulations." - Data Bridge Market Research[2]

Key Takeaways

  • Clinical Efficacy: Lidocaine and tetracaine patches and creams have shown significant efficacy in pain management during various medical procedures.
  • Market Growth: The global lidocaine market is expected to grow substantially, driven by advancements in formulation technologies and increasing demand for pain relief solutions.
  • Regional Expansion: The Asia-Pacific region is poised to be a key growth area due to rising demand for cosmetic and surgical procedures.
  • Safety and Efficacy: Innovations in lidocaine formulations are improving safety and efficacy, making them preferred choices for pain management.

FAQs

What are the primary applications of lidocaine and tetracaine?

Lidocaine and tetracaine are primarily used for local anesthesia, pain management, and as antiarrhythmic agents. They are applied in various medical fields including dentistry, cardiac arrhythmia treatment, and cosmetic procedures.

How effective are lidocaine and tetracaine patches in pain management?

Studies have shown that lidocaine and tetracaine patches are effective in reducing pain during procedures such as lumbar punctures and cosmetic injections. However, they may require longer recovery times compared to placebo patches[1].

What are the future growth drivers for the lidocaine market?

The market is expected to grow due to advancements in delivery systems, increasing surgical and dental procedures, and the growing acceptance of lidocaine for cosmetic applications[2].

Are there any regional differences in the adoption of lidocaine formulations?

Yes, the Asia-Pacific region is projected to be the fastest-growing market for lidocaine formulations, driven by the increasing number of dental procedures, cosmetic treatments, and plastic surgeries[2].

What are the potential challenges for the lidocaine market?

Despite the growth potential, the market faces challenges such as adverse reactions and side effects. However, advancements in formulation technologies are mitigating these risks[2].

Sources

  1. Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients With Blood Cancer. Journal of Hospital Medicine, February 2022.
  2. Global Lidocaine Market Size, Share, Trends, & Report Analysis By 2031. Data Bridge Market Research.
  3. U.S. Clinical Trials Market Size Industry Analysis Report, 2033. BioSpace.
  4. Evaluation of the Efficacy and Safety of a Lidocaine and Tetracaine 7%7% Cream for Induction of Local Dermal Anesthesia for Facial Soft Tissue Augmentation With Hyaluronic Acid. Journal of Clinical and Aesthetic Dermatology.
  5. Local Anesthesia Drugs Market Size & Share Report, 2030. Grand View Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.